{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:07Z","timestamp":1790902447857,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00105-026-05777-0","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:41:19Z","timestamp":1790091679000},"page":"639-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vulv\u00e4re intraepitheliale Neoplasien und Vulvakarzinome","Vulvar intraepithelial neoplasia and vulvar cancer"],"prefix":"10.1007","volume":"77","author":[{"given":"M.","family":"Hampl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"W\u00f6lber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"5777_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1055\/a-1545-4279","volume":"81","author":"AK H\u00f6hn","year":"2021","unstructured":"H\u00f6hn AK et al (2021) 2020 WHO Classification of Female Genital Tumors. Geburtsh Frauenheilk 81:1145\u20131153","journal-title":"Geburtsh Frauenheilk"},{"issue":"2","key":"5777_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ygyno.2005.02.012","volume":"97","author":"M van Seters","year":"2005","unstructured":"van Seters\u00a0M, van Beurden\u00a0M, de Craen\u00a0AJ (2005) Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 97(2):645\u2013651","journal-title":"Gynecol Oncol"},{"issue":"9","key":"5777_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2020.101801","volume":"49","author":"M Lebreton","year":"2020","unstructured":"Lebreton\u00a0M et\u00a0al (2020) Vulvar intraepithelial neoplasia: Classification, epidemiology, diagnosis, and management. J\u00a0Gynecol Obstet Hum Reprod 49(9):101801","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"10","key":"5777_CR4","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/ijc.33459","volume":"148","author":"NB Thuijs","year":"2021","unstructured":"Thuijs\u00a0NB et\u00a0al (2021) DNA methylation markers for cancer risk prediction of vulvar intraepithelial neoplasia. Int J Cancer 148(10):2481\u20132488","journal-title":"Int J Cancer"},{"issue":"7","key":"5777_CR5","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1055-9965.EPI-09-0209","volume":"18","author":"HP van de Nieuwenhof","year":"2009","unstructured":"van de Nieuwenhof\u00a0HP et\u00a0al (2009) The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol Biomarkers Prev 18(7):2061\u20132067","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"5777_CR6","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/ijc.30900","volume":"141","author":"YJ Kang","year":"2017","unstructured":"Kang\u00a0YJ et\u00a0al (2017) Vulvar cancer in high-income countries: Increasing burden of disease. Int J Cancer 141(11):2174\u20132186","journal-title":"Int J Cancer"},{"issue":"3","key":"5777_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ygyno.2017.03.008","volume":"145","author":"CJ Meltzer-Gunnes","year":"2017","unstructured":"Meltzer-Gunnes\u00a0CJ et\u00a0al (2017) Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival. Gynecol Oncol 145(3):543\u2013548","journal-title":"Gynecol Oncol"},{"issue":"6","key":"5777_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ijc.30821","volume":"141","author":"MT Faber","year":"2017","unstructured":"Faber\u00a0MT et\u00a0al (2017) Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer 141(6):1161\u20131169","journal-title":"Int J Cancer"},{"issue":"3","key":"5777_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ygyno.2022.06.014","volume":"166","author":"CL Rasmussen","year":"2022","unstructured":"Rasmussen\u00a0CL et\u00a0al (2022) Changes in HPV prevalence in Danish women with vulvar cancer during 28\u00a0years - A nationwide study of \u3009\u202f1300 cancer cases. Gynecol Oncol 166(3):589\u2013595","journal-title":"Gynecol Oncol"},{"issue":"16","key":"5777_CR10","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1016\/j.ejca.2013.06.033","volume":"49","author":"S de Sanjose","year":"2013","unstructured":"de Sanjose\u00a0S et\u00a0al (2013) Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 49(16):3450\u20133461","journal-title":"Eur J Cancer"},{"issue":"8","key":"5777_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1158\/1055-9965.EPI-16-0019","volume":"25","author":"MC Bleeker","year":"2016","unstructured":"Bleeker\u00a0MC et\u00a0al (2016) Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev 25(8):1224\u20131230","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"5777_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/LGT.0000000000000572","volume":"25","author":"DS Heller","year":"2021","unstructured":"Heller\u00a0DS et\u00a0al (2021) Diagnostic Criteria for Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. J\u00a0Low Genit Tract Dis 25(1):57\u201370","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"5777_CR13","doi-asserted-by":"publisher","first-page":"595 e1","DOI":"10.1016\/j.ajog.2020.12.1220","volume":"224","author":"L Woelber","year":"2021","unstructured":"Woelber\u00a0L et\u00a0al (2021) p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynakologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. Am J Obstet Gynecol 224(6):595 e1\u2013595 e11","journal-title":"Am J Obstet Gynecol"},{"key":"5777_CR14","doi-asserted-by":"crossref","unstructured":"Prieske K et\u00a0al (2021) Transcriptome Analysis in Vulvar Squamous Cell Cancer. Cancers (Basel) 13(24).","DOI":"10.3390\/cancers13246372"},{"issue":"3","key":"5777_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ygyno.2020.09.024","volume":"159","author":"KE Kortekaas","year":"2020","unstructured":"Kortekaas\u00a0KE et\u00a0al (2020) Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol 159(3):649\u2013656","journal-title":"Gynecol Oncol"},{"issue":"2","key":"5777_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ygyno.2018.03.003","volume":"149","author":"F Hinten","year":"2018","unstructured":"Hinten\u00a0F et\u00a0al (2018) Vulvar cancer: Two pathways with different localization and prognosis. Gynecol Oncol 149(2):310\u2013317","journal-title":"Gynecol Oncol"},{"issue":"3","key":"5777_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ygyno.2016.06.019","volume":"142","author":"JK Yap","year":"2016","unstructured":"Yap\u00a0JK et\u00a0al (2016) Adjacent Lichen Sclerosis predicts local recurrence and second field tumour in women with vulvar squamous cell carcinoma. Gynecol Oncol 142(3):420\u2013426","journal-title":"Gynecol Oncol"},{"issue":"1","key":"5777_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/ijgc-2019-000793","volume":"30","author":"L Proctor","year":"2020","unstructured":"Proctor\u00a0L et\u00a0al (2020) Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. Int J Gynecol Cancer 30(1):100\u2013106","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"5777_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijrobp.2018.08.014","volume":"103","author":"MJ Dohopolski","year":"2019","unstructured":"Dohopolski\u00a0MJ et\u00a0al (2019) The Prognostic Significance of p16 Status in Patients With Vulvar Cancer Treated With Vulvectomy and Adjuvant Radiation. Int J Radiat Oncol Biol Phys 103(1):152\u2013160","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5777_CR20","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e27","volume":"28","author":"M Preti","year":"2017","unstructured":"Preti\u00a0M et\u00a0al (2017) Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy. J\u00a0Gynecol Oncol 28(4):e27","journal-title":"J Gynecol Oncol"},{"key":"5777_CR21","doi-asserted-by":"crossref","unstructured":"Thuijs NB et\u00a0al (2020) Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer","DOI":"10.1136\/ijgc-2019-ESGO.247"},{"issue":"5","key":"5777_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ejca.2008.11.037","volume":"45","author":"HP van de Nieuwenhof","year":"2009","unstructured":"van de Nieuwenhof\u00a0HP et\u00a0al (2009) Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer 45(5):851\u2013856","journal-title":"Eur J Cancer"},{"issue":"9","key":"5777_CR23","first-page":"766","volume":"44","author":"RW Jones","year":"1999","unstructured":"Jones\u00a0RW, Joura\u00a0EA (1999) Analyzing prior clinical events at presentation in 102 women with vulvar carcinoma. Evidence of diagnostic delays. J\u00a0Reprod Med 44(9):766\u2013768","journal-title":"J Reprod Med"},{"issue":"9","key":"5777_CR24","doi-asserted-by":"publisher","first-page":"8725","DOI":"10.18632\/oncotarget.23848","volume":"9","author":"J Muigai","year":"2018","unstructured":"Muigai\u00a0J et\u00a0al (2018) Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices. Oncotarget 9(9):8725\u20138730","journal-title":"Oncotarget"},{"issue":"1","key":"5777_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100007","volume":"35","author":"M Preti","year":"2025","unstructured":"Preti\u00a0M et\u00a0al (2025) Vulvar inspection at the time of cervical cancer screening: European Society of Gynaecological Oncology (ESGO), International Society for the Study of Vulvovaginal Disease (ISSVD), European College for the Study of Vulval Disease (ECSVD), and European Federation for Colposcopy (EFC) consensus statements. Int J Gynecol Cancer 35(1):100007","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"5777_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/01.AOG.0000187301.76283.7f","volume":"106","author":"RW Jones","year":"2005","unstructured":"Jones\u00a0RW, Rowan\u00a0DM, Stewart\u00a0AW (2005) Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106(6):1319\u20131326","journal-title":"Obstet Gynecol"},{"issue":"8","key":"5777_CR27","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1097\/IGC.0b013e3182a57fd6","volume":"23","author":"EM van Esch","year":"2013","unstructured":"van Esch\u00a0EM et\u00a0al (2013) Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia. Int J Gynecol Cancer 23(8):1476\u20131483","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"5777_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ygyno.2017.10.029","volume":"148","author":"W Satmary","year":"2018","unstructured":"Satmary\u00a0W et\u00a0al (2018) Vulvar intraepithelial neoplasia: Risk factors for recurrence. Gynecol Oncol 148(1):126\u2013131","journal-title":"Gynecol Oncol"},{"issue":"4","key":"5777_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/LGT.0b013e318284c1ed","volume":"17","author":"L Leufflen","year":"2013","unstructured":"Leufflen\u00a0L et\u00a0al (2013) Treatment of vulvar intraepithelial neoplasia with CO(2) laser vaporization and excision surgery. J\u00a0Low Genit Tract Dis 17(4):446\u2013451","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"5777_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ygyno.2005.08.012","volume":"100","author":"P Hillemanns","year":"2006","unstructured":"Hillemanns\u00a0P et\u00a0al (2006) Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 100(2):271\u2013275","journal-title":"Gynecol Oncol"},{"issue":"7","key":"5777_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/ijgc-2021-003262","volume":"32","author":"M Preti","year":"2022","unstructured":"Preti\u00a0M, The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), the European Federation for Colposcopy (EFC) et\u00a0al (2022) consensus statements on pre-invasive vulvar lesions. Int J Gynecol Cancer 32(7):830\u2013845","journal-title":"Int J Gynecol Cancer"},{"issue":"14","key":"5777_CR32","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa072685","volume":"358","author":"M van Seters","year":"2008","unstructured":"van Seters\u00a0M et\u00a0al (2008) Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 358(14):1465\u20131473","journal-title":"N Engl J Med"},{"issue":"1","key":"5777_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ygyno.2010.12.340","volume":"121","author":"A Terlou","year":"2011","unstructured":"Terlou\u00a0A et\u00a0al (2011) Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol 121(1):157\u2013162","journal-title":"Gynecol Oncol"},{"issue":"10337","key":"5777_CR34","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/S0140-6736(22)00469-X","volume":"399","author":"G Trutnovsky","year":"2022","unstructured":"Trutnovsky\u00a0G et\u00a0al (2022) Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial. Lancet 399(10337):1790\u20131798","journal-title":"Lancet"},{"issue":"4","key":"5777_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/lsm.10048","volume":"30","author":"MK Fehr","year":"2002","unstructured":"Fehr\u00a0MK et\u00a0al (2002) Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5\u2011aminolevulinic acid. Lasers Surg Med 30(4):273\u2013279","journal-title":"Lasers Surg Med"},{"key":"5777_CR36","doi-asserted-by":"crossref","unstructured":"Ansink A and van der Velden J (2000) Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev (2): p. CD002036.","DOI":"10.1002\/14651858.CD002036"},{"issue":"7","key":"5777_CR37","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/ijgc-2023-004486","volume":"33","author":"MHM Oonk","year":"2023","unstructured":"Oonk\u00a0MHM et\u00a0al (2023) European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023. Int J Gynecol Cancer 33(7):1023\u20131043","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"5777_CR38","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1200\/JCO.23.02235","volume":"42","author":"NS Horowitz","year":"2024","unstructured":"Horowitz\u00a0NS et\u00a0al (2024) Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology\/GOG Study 279. J\u00a0Clin Oncol 42(16):1914\u20131921","journal-title":"J Clin Oncol"},{"issue":"1","key":"5777_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02523-5","volume":"18","author":"O Yeku","year":"2020","unstructured":"Yeku\u00a0O et\u00a0al (2020) A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma. J\u00a0Transl Med 18(1):350","journal-title":"J Transl Med"},{"key":"5777_CR40","doi-asserted-by":"crossref","unstructured":"Mahner S et\u00a0al (2015) Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1\u00a0study. J\u00a0Natl Cancer Inst 107(3).","DOI":"10.1093\/jnci\/dju426"},{"issue":"6","key":"5777_CR41","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2007.14.0566","volume":"26","author":"AG Van der Zee","year":"2008","unstructured":"Van der Zee\u00a0AG et\u00a0al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J\u00a0Clin Oncol 26(6):884\u2013889","journal-title":"J Clin Oncol"},{"issue":"31","key":"5777_CR42","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1200\/JCO.2011.41.2528","volume":"30","author":"CF Levenback","year":"2012","unstructured":"Levenback\u00a0CF et\u00a0al (2012) Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a\u00a0gynecologic oncology group study. J\u00a0Clin Oncol 30(31):3786\u20133791","journal-title":"J Clin Oncol"},{"key":"5777_CR43","unstructured":"Oonk MHM et\u00a0al (2021) Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS\u2011V II. J\u00a0Clin Oncol p. JCO2100006."},{"issue":"1","key":"5777_CR44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ygyno.2021.11.004","volume":"164","author":"L Woelber","year":"2022","unstructured":"Woelber\u00a0L et\u00a0al (2022) Adjuvant radiotherapy and local recurrence in vulvar cancer - a\u00a0subset analysis of the AGO-CaRE-1\u00a0study. Gynecol Oncol 164(1):68\u201375","journal-title":"Gynecol Oncol"},{"issue":"3","key":"5777_CR45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ygyno.2015.03.056","volume":"137","author":"BS Gill","year":"2015","unstructured":"Gill\u00a0BS et\u00a0al (2015) Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A\u00a0National Cancer Data Base (NCDB) analysis. Gynecol Oncol 137(3):365\u2013372","journal-title":"Gynecol Oncol"},{"issue":"8","key":"5777_CR46","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari\u00a0KS et\u00a0al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370(8):734\u2013743","journal-title":"N Engl J Med"},{"issue":"20","key":"5777_CR47","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo\u00a0N et\u00a0al (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 385(20):1856\u20131867","journal-title":"N Engl J Med"},{"key":"5777_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1352975","volume":"14","author":"R Schwab","year":"2024","unstructured":"Schwab\u00a0R et\u00a0al (2024) Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-arm meta-analysis. Front Oncol 14:1352975","journal-title":"Front Oncol"},{"issue":"3","key":"5777_CR49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ygyno.2017.11.006","volume":"148","author":"NC te Grootenhuis","year":"2018","unstructured":"te Grootenhuis\u00a0NC et\u00a0al (2018) Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review. Gynecol Oncol 148(3):622\u2013631","journal-title":"Gynecol Oncol"},{"issue":"9574","key":"5777_CR50","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","volume":"369","author":"EA Joura","year":"2007","unstructured":"Joura\u00a0EA et\u00a0al (2007) Efficacy of a\u00a0quadrivalent prophylactic human papillomavirus (types\u00a06, 11, 16, and\u00a018) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a\u00a0combined analysis of three randomised clinical trials. Lancet 369(9574):1693\u20131702","journal-title":"Lancet"},{"issue":"1","key":"5777_CR51","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2567704","volume":"21","author":"R Montero-Macias","year":"2025","unstructured":"Montero-Macias\u00a0R et\u00a0al (2025) HPV vaccination efficacy in primary and tertiary prevention of vulvar and vaginal HPV-related high grade dysplasia and cancers: A systematic review. Hum Vaccin Immunother 21(1):2567704","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"5777_CR52","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jamadermatol.2015.0643","volume":"151","author":"A Lee","year":"2015","unstructured":"Lee\u00a0A, Bradford\u00a0J, Fischer\u00a0G (2015) Long-term Management of Adult Vulvar Lichen Sclerosus: A Prospective Cohort Study of 507 Women. JAMA Dermatol 151(10):1061\u20131067","journal-title":"JAMA Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05777-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05777-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05777-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:16Z","timestamp":1790899456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05777-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5777"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05777-0","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"1 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Hampl erkl\u00e4rt, dass sie sich bei der Erstellung des Beitrages nicht von wirtschaftlichen Interessen leiten lie\u00df. Sie legt die folgenden potenziellen Interessenkonflikte offen: Innerhalb der letzten 3\u00a0Jahre erhielt sie pers\u00f6nliche Honorare (Beratung\/Vortr\u00e4ge) und\/oder Reisekostenunterst\u00fctzung von Roche, AstraZeneca, MSD, Exeltis. L.\u00a0W\u00f6lber erkl\u00e4rt, dass sie sich bei der Erstellung des Beitrages nicht von wirtschaftlichen Interessen leiten lie\u00df. Sie legt die folgenden potenziellen Interessenkonflikte offen: Innerhalb der letzten 3\u00a0Jahre erhielt sie pers\u00f6nliche Honorare (Beratung\/Vortr\u00e4ge) und\/oder Reisekostenunterst\u00fctzung von Roche, Eisai, Novartis, MSD, GSK, AstraZeneca, Pfizer, Lumenis, medupdate GmbH, Regeneron, AbbVie, Genmab. Gelder f\u00fcr wissenschaftliche Projekte erhielt sie bzw. ihre Institution von der DKH, Hamburger Krebsgesellschaft, Lumenis, MSD, Roche, GILEAD, AstraZeneca.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}